Medicare Covers GLP-1 Weight-Loss Drugs Starting July 1

For the first time in the program's history, older Americans enrolled in Medicare will gain access to GLP-1 weight-loss medications starting July 1, with qualifying beneficiaries able to obtain the drugs for as little as $50 per month — a landmark shift in federal health coverage that could affect millions of seniors struggling with obesity.

The new benefit marks a significant expansion of Medicare's drug coverage, which previously covered GLP-1 medications like semaglutide only for diabetes management, not for weight loss alone. Qualifying beneficiaries who meet clinical criteria will now be able to fill prescriptions at the reduced monthly cost, making treatments that can otherwise run hundreds or thousands of dollars per month far more accessible to those on fixed incomes.

Read more Conservation Easements: When the Tax Break Still Works in 2024 →

However, health experts caution that the drugs come with important considerations beyond the price tag. GLP-1 medications are associated with side effects including nausea, vomiting, and gastrointestinal discomfort, and seniors in particular face an elevated risk of muscle mass loss — a condition known as sarcopenia — which can compound mobility and strength challenges already common in older adults.

Financial and medical advisers suggest that prospective users discuss the full risk-benefit picture with their physicians before starting treatment, and consider pairing the medication with resistance exercise and adequate protein intake to help preserve lean muscle. For a demographic already navigating complex health needs, the decision involves more than simply meeting a cost threshold.

The rollout represents one of the most consequential expansions of Medicare drug benefits in recent years, arriving as GLP-1 drugs have reshaped both the pharmaceutical market and public conversations around weight management. Continue reading at MarketWatch.com.